ExploreWatchlistsPricing
  1. JP-listed companies
  2. SEIKAGAKU CORPORATION
  3. Financials
  4. Gross margin (%)

SEIKAGAKU CORPORATION (4548)

Market cap
¥45B
P/E ratio
19.2x
Develops and manufactures pharmaceuticals for joint care, eye surgery, and spinal treatments, plus specialized LAL testing reagents that ensure drug safety.
SummaryFinancialsDividendsHistoryOwnershipWorkforce
Period EndGross margin (%) YoY (%)
Mar 31, 202643.6-10.40%
Mar 31, 202548.6+4.38%
Mar 31, 202446.6-13.49%
Mar 31, 202353.9-8.54%
Mar 31, 202258.9+4.79%
Mar 31, 202156.2-0.18%
Mar 31, 202056.3+4.67%
Mar 31, 201953.8-5.43%
Mar 31, 201856.9+3.01%
Mar 31, 201755.2-5.48%
Mar 31, 201658.4-0.81%
Mar 31, 201558.9

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat